Department of Clinical Pharmacy, Faculty of Pharmacy, University of Sadat City, Sadat City, Egypt.
Department of Biochemistry, Faculty of Pharmacy, Menoufia University, Shebeen El-Kom, Egypt.
CNS Neurosci Ther. 2023 Jan;29(1):354-364. doi: 10.1111/cns.14010. Epub 2022 Nov 7.
The aim of this study was to explore the effectiveness and safety of pentoxifylline as an adjuvant to risperidone in mitigating the negative symptoms in patients with chronic schizophrenia.
In this randomized, placebo-controlled study, eighty outpatients with chronic schizophrenia were given risperidone for 8 weeks along with either pentoxifylline or a placebo. The positive and negative syndrome scale (PANSS) was used to assess patients at the start of the trial, as well as at 2, 4, 6, and 8 weeks. Pre- and posttreatment serum levels of cAMP, TNF-α-, and IL-6 were measured.
The pentoxifylline group revealed a significant effect for time-treatment interaction on PANSS-negative subscale scores (p < 0.001), PANSS general psychopathology subscale scores (p < 0.001), and PANSS total scores (p < 0.001), but not on PANSS-positive subscale scores (p = 0.169). Additionally, when compared to the placebo group, the pentoxifylline group demonstrated a statistically significant increase in cAMP serum level and a statistically significant decrease in TNF-α and IL-6 serum levels.
Pentoxifylline adjunctive therapy with risperidone for 8 weeks was found to be promising in mitigating the negative symptoms in patients with chronic schizophrenia.
NCT04094207.
本研究旨在探讨己酮可可碱作为利培酮辅助治疗药物对慢性精神分裂症患者阴性症状的疗效和安全性。
这是一项随机、安慰剂对照研究，共纳入 80 例慢性精神分裂症门诊患者，给予利培酮治疗 8 周，同时给予己酮可可碱或安慰剂。采用阳性和阴性症状量表（PANSS）在试验开始时以及第 2、4、6 和 8 周对患者进行评估。测量治疗前后血清中环磷酸腺苷（cAMP）、肿瘤坏死因子-α（TNF-α）和白细胞介素-6（IL-6）的水平。
己酮可可碱组在 PANSS 阴性症状量表评分（p<0.001）、PANSS 一般精神病理量表评分（p<0.001）和 PANSS 总分（p<0.001）上均显示出时间-治疗交互作用的显著效果，但在 PANSS 阳性症状量表评分上无显著差异（p=0.169）。与安慰剂组相比，己酮可可碱组的血清 cAMP 水平显著升高，TNF-α和 IL-6 水平显著降低。
己酮可可碱辅助利培酮治疗 8 周可能对慢性精神分裂症患者的阴性症状有改善作用。
NCT04094207。
Zotero 插件